Breast cancer (BRCA-mutated)
- Treat by stage + receptor status first
- Germline BRCA can create PARP-inhibitor eligibility
- Olaparib is important in selected high-risk early disease
- PARP inhibitors also treat selected metastatic HER2-negative disease
- Platinum sensitivity can be clinically relevant
- Genetic counseling/family testing are part of care
Use at a glance
- Treat by stage + receptor status first
Practical pearls
- Germline BRCA can create PARP-inhibitor eligibility
- Platinum sensitivity can be clinically relevant
- Genetic counseling/family testing are part of care
Choosing treatment
- PARP inhibitors also treat selected metastatic HER2-negative disease
Treatment selection
- Olaparib is important in selected high-risk early disease
Self-check
- Which PARP inhibitor treats selected high-risk early BRCA breast cancer?
Olaparib. - What first guides BRCA breast-cancer treatment?
Stage + receptor status.
Drugs used for this (1)
All clinical uses · Open Breast cancer (BRCA-mutated) in the interactive console ↗